Considering that the use of a single protein as a biomarker has the limitations of both sensitivity and specificity, the combination of HSP90α, AFP and potentially another clinical index or biomarker might improve the diagnostic efficiency and staging determination for HCC in the future. This evidence concerns the gene AFP and hepatocellular carcinoma.